Tag
The article reports on the severe Ebola outbreak in the Democratic Republic of Congo, with over 7,000 cases and half deaths, and highlights the concerns of organizations like CEPI as they rush to develop vaccines amidst challenges of distrust and instability.
An HIV vaccine developed by La Jolla Institute for Immunology and Scripps Research has shown unprecedented success in generating broadly neutralizing antibodies in primates, with human trials now underway.
Researchers at the University of Cambridge have developed the first entirely AI-designed vaccine, which targets entire virus families and has successfully completed a Phase I human trial showing safety and broad immune response.
Moderna received $50 million from CEPI to develop an mRNA Ebola vaccine targeting the Bundibugyo strain, amid a severe outbreak in DRC with over 1,000 cases and 241 deaths.